BeiGene, Ltd. (ONC)vsOS Therapies Incorporated (OSTX)
ONC
BeiGene, Ltd.
$283.45
+2.81%
HEALTHCARE · Cap: $31.62B
OSTX
OS Therapies Incorporated
$1.44
+4.35%
HEALTHCARE · Cap: $53.53M
Smart Verdict
WallStSmart Research — data-driven comparison
ONC leads profitability with a 5.4% profit margin vs 0.0%. ONC earns a higher WallStSmart Score of 42/100 (D).
ONC
Hold42
out of 100
Grade: D
OSTX
Avoid16
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-1983.5%
Fair Value
$16.86
Current Price
$283.45
$266.59 premium
Intrinsic value data unavailable for OSTX.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Revenue surging 32.8% year-over-year
Conservative balance sheet, low leverage
No standout strengths identified
Areas to Watch
0.0% earnings growth
ROE of 7.5% — below average capital efficiency
5.4% margin — thin
Premium valuation, high expectations priced in
Trading at 13.1x book value
0.0% revenue growth
0.0% earnings growth
Smaller company, higher risk/reward
Comparative Analysis Report
WallStSmart ResearchBull Case : ONC
The strongest argument for ONC centers on Revenue Growth, Debt/Equity. Revenue growth of 32.8% demonstrates continued momentum.
Bull Case : OSTX
OSTX has a balanced fundamental profile.
Bear Case : ONC
The primary concerns for ONC are EPS Growth, Return on Equity, Profit Margin. A P/E of 111.0x leaves little room for execution misses.
Bear Case : OSTX
The primary concerns for OSTX are Price/Book, Revenue Growth, EPS Growth.
Key Dynamics to Monitor
ONC profiles as a hypergrowth stock while OSTX is a value play — different risk/reward profiles.
ONC is growing revenue faster at 32.8% — sustainability is the question.
ONC generates stronger free cash flow (131M), providing more financial flexibility.
Monitor BIOTECHNOLOGY industry trends, competitive dynamics, and regulatory changes.
Bottom Line
ONC scores higher overall (42/100 vs 16/100) and 32.8% revenue growth. Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
BeiGene, Ltd.
HEALTHCARE · BIOTECHNOLOGY · USA
BeiGene, Ltd., an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company is headquartered in Camana Bay, the Cayman Islands.
Visit Website →OS Therapies Incorporated
HEALTHCARE · BIOTECHNOLOGY · USA
OS Therapies Incorporated is a biopharmaceutical innovator focused on developing groundbreaking treatments for patients with unmet medical needs, particularly in the neurological disorder space. The company has a robust pipeline powered by its proprietary drug development technologies, which aim to enhance patient outcomes and overall quality of life. With a steadfast commitment to research excellence and a strategic emphasis on high-impact therapeutic areas, OS Therapies represents a compelling investment opportunity for institutional investors seeking to engage in the dynamic and evolving biotech sector.
Visit Website →Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?